Medicare Molecular Diagnostic (MolDX) Coverage: Z-Codes, Billing, and Appeals

Medicare MolDX coverage is the framework that decides whether Medicare will pay for a specific molecular or genetic test. Administered by Palmetto GBA on behalf of several Medicare Administrative Contractors, the Molecular Diagnostic Services program requires each test to be registered under a unique identifier, pass an evidence review, and be billed in a particular way before a claim will be paid.¹ The program exists because standard CPT codes cannot distinguish among the thousands of molecular tests on the market, many of which share a billing code despite measuring very different things.

Which Tests MolDX Applies To

MolDX covers tests that detect or identify DNA, RNA, proteins, chromosomes, enzymes, chemotherapy sensitivity markers, or other metabolites. A single mutation analysis counts. So does a multi-gene panel that runs results through an interpretive algorithm.²

Within that broad definition, the program specifically applies to:

Laboratory-developed tests created and validated in-house rather than sold as an FDA-cleared kit.
FDA-cleared kits that a laboratory has modified from the manufacturer’s instructions.
Tests billed with more than one CPT or HCPCS code, including combinations of methodology, serology, and anatomic pathology codes.
Tests billed with the “not otherwise classified” codes 81479, 81599, and 87999.

If a molecular-level test fits any of those descriptions, it falls within MolDX scope.²

Where MolDX Applies

The program runs through specific Medicare Administrative Contractors: Palmetto GBA, Noridian Healthcare Solutions, CGS Administrators, and Wisconsin Physicians Service Insurance Corporation. Each handles claims in its assigned territory, but all apply a unified set of MolDX rules.

One jurisdictional rule catches many laboratories off guard. Coverage follows the location of the testing facility, not where the patient lives or where the ordering physician practices. A lab in a Palmetto GBA jurisdiction applies Palmetto’s Local Coverage Determinations even when the specimen comes from a patient across the country. Participating contractors keep their coverage policies aligned so a test treated as covered in one MolDX region is generally treated the same elsewhere, but confirming the specific MAC’s policies is still the lab’s responsibility. MACs that do not participate in MolDX apply their own local policies, which may use different evaluation standards and billing requirements.

Registering a Test and Getting a Z-Code

Before billing Medicare for any molecular test, a laboratory must register the test on the DEX Diagnostics Exchange, an online registry run by Palmetto GBA.³ The lab must hold Clinical Laboratory Improvement Amendments (CLIA) certification to be eligible.⁴

Each registered test receives a DEX Z-Code: a five-character alphanumeric identifier that distinguishes one lab’s test from similar assays elsewhere. Z-Codes attach to the orderable test or panel, not to each CPT code within it. A 50-gene panel ordered as one test gets one Z-Code.³

Registration captures the lab’s credentials, the methodology and technology, the genetic targets, and the intended clinical use. Labs running the same test at multiple sites under different CLIA numbers should expect to register each location separately.

How Tests Are Evaluated for Coverage

After registration, the lab submits a Technical Assessment package through Palmetto GBA’s secure portal or an encrypted email channel specified by the program.⁵ Not every registered test needs a full submission. Tests that do not require additional documentation move through review in roughly three to four weeks; tests that submit Technical Assessment documentation can take up to 60 days.⁶ Incomplete packages are returned before substantive review begins.

Reviewers apply three standards, grounded in the Social Security Act’s requirement that Medicare only cover services “reasonable and necessary for the diagnosis or treatment of illness or injury”:⁷

Analytical validity: whether the test accurately and reliably detects what it claims to detect.
Clinical validity: whether results actually correspond to the presence or absence of the disease or condition.
Clinical utility: whether results change patient management or outcomes. Most tests face their toughest scrutiny here. A result that confirms a diagnosis without changing treatment is viewed as having limited utility.

Reviewers weigh peer-reviewed literature and clinical trial data. For oncology tests, evaluators look for evidence aligned with guidelines from bodies such as the American Society of Clinical Oncology and the National Comprehensive Cancer Network.⁸ A test without a clear impact on patient management is classified as investigational or non-covered.

Billing a MolDX Test

Approval does not pay the claim; correct billing does. Every claim for a molecular test within MolDX must carry both the appropriate CPT or HCPCS code and the test’s DEX Z-Code. The Z-Code goes in specific fields depending on the claim type: the SV101-7 segment for electronic professional claims, the SV202-7 segment for institutional claims, and block 80 on paper UB-04 forms.⁵⁶

A missing or invalid Z-Code causes the MAC to reject the claim outright. For Part B claims, do not add extra characters to the SV101-7 field alongside the Z-Code; stray information on that line is a common source of rejections.⁵

How Payment Rates Are Set

For molecular tests that do not have an established payment on the Clinical Laboratory Fee Schedule, MolDX contractors use an Equitable Pricing Model to produce gapfill rates. The algorithm follows the pricing factors required under 42 CFR 414, Subpart G:⁹

The lab’s charges and any routine discounts.
Resources required to perform the test, including reagents, equipment, and labor.
Payment amounts other payers have set for the test.
Charges, payments, and resource use for comparable tests on the market.

Many novel molecular tests enter the market this way, with their initial Medicare rate calculated through the model.

Checking Coverage Before Ordering a Test

Two tools let ordering providers and patients confirm coverage before a specimen is drawn. The Medicare Coverage Database at CMS.gov is searchable by CPT or HCPCS code and filterable by state, and returns the applicable Local Coverage Determinations and Billing and Coding Articles.¹⁰ The DEX portal has a search function that returns a Z-Code’s current status: covered, non-covered, or investigational.³ Checking both before the test runs tells the provider whether the documentation will support the claim and tells the patient whether an out-of-pocket charge is likely.

When Medicare Will Not Pay

If a molecular test is classified as investigational or non-covered, Medicare pays nothing. The patient becomes responsible, but only if the provider sets that up correctly in advance. Under Original Medicare, a provider who expects a denial should issue an Advance Beneficiary Notice of Noncoverage (CMS Form R-131) before performing the test. The notice explains that Medicare may not pay, gives an estimated cost, and lets the patient decide whether to go ahead.

Without a properly executed ABN, the provider may not be able to bill the patient for the denied service. When coverage is uncertain, the ordering physician and the performing lab should coordinate to make sure the notice is signed before the test runs.

Keeping Coverage After Approval

A coverage determination is not permanent. Labs must notify MolDX, and may need to submit updated Technical Assessment documentation, when any of the following happens:⁶

The test itself changes: gene content, methodology, intended clinical use, or accepted specimen types.
The lab relocates.
MolDX issues a new coverage policy that reaches previously approved test categories.

If a change is significant enough that the test is effectively a new product, Palmetto GBA may assign a new Z-Code rather than update the existing one. Methodology changes and new specimen types are common triggers.⁶ Labs that fail to report material changes risk claim denials or revoked coverage.

Challenging a Negative Decision

There are two different routes, and they address two different problems.

Appealing a Denied Claim

If an individual claim with a valid Z-Code is denied, the standard Medicare appeals process applies. The five levels run from redetermination by the MAC, through reconsideration by a Qualified Independent Contractor, a hearing before the Office of Medicare Hearings and Appeals, and review by the Medicare Appeals Council, to judicial review in federal district court. Each level must be exhausted before the next. A redetermination request must be filed within 120 calendar days of receiving the denial notice; receipt is presumed to be five days after the notice date unless shown otherwise.¹¹

Requesting an LCD Reconsideration

When the problem is the coverage policy itself rather than a single claim, labs and other stakeholders can ask the MAC to reconsider or modify the Local Coverage Determination. The request must be in writing and include copies of published evidence supporting the change.¹² Reconsideration requests that include new clinical data are assessed on receipt, and even finalized policies remain open to revision through this process. For labs whose tests were initially called investigational, a well-supported reconsideration request is often the more productive path.

1
Palmetto GBA. Innovation and Standardization for Molecular Diagnostic Testing
2
Centers for Medicare & Medicaid Services. LCD – MolDX: Molecular Diagnostic Tests (MDT) (L35025)
3
Palmetto GBA. DEX Registry Getting Started Guide
4
Centers for Medicare & Medicaid Services. Response to Comments: MolDX: Minimal Residual Disease Testing for Cancer
5
Palmetto GBA. MolDX: Coverage, Coding, and Pricing Standards and Requirements
6
Palmetto GBA. MolDX – Frequently Asked Questions
7
Social Security Administration. Social Security Act Title 18 – 1862
8
Centers for Medicare & Medicaid Services. MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells (L38678)
9
Palmetto GBA. Equitable Pricing Model – MolDX
10
Centers for Medicare & Medicaid Services. Medicare Coverage Database
11
eCFR. 42 CFR Part 405 Subpart I – Determinations, Redeterminations, Reconsiderations, and Appeals Under Original Medicare
12
Centers for Medicare & Medicaid Services. Response to Comments: MolDX: Molecular Diagnostic Tests (MDT)